2. Search Result
Search Result
Results for "

anticoagulant effects

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Biochemical Assay Reagents

5

Peptides

2

Inhibitory Antibodies

4

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1929
    Bivalirudin
    Maximum Cited Publications
    9 Publications Verification

    		 Thrombin Interleukin Related RSV Infection Cardiovascular Disease Inflammation/Immunology
    Bivalirudin, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin can be used for the research of thrombotic diseases and others .
    Bivalirudin
  • HY-10274
    Dabigatran etexilate
    4 Publications Verification

    BIBR 1048

    		 Thrombin Cardiovascular Disease
    Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate
  • HY-P2813
    Hirudin
    3 Publications Verification

    		 Thrombin Apoptosis Cardiovascular Disease Cancer
    Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others .
    Hirudin
  • HY-D0836
    EDTA dipotassium dihydrate
    25+ Cited Publications

    Ethylenediaminetetraacetic acid dipotassium dihydrate

    		 DNA/RNA Synthesis Others
    EDTA dipotassium dihydrate is a metal ion chelator that forms stable and water-soluble chelates with a variety of metal ions. EDTA dipotassium is commonly used as a blood anticoagulant, which can effectively prevent blood coagulation and maintain the morphology and function of cells in blood samples. In the industrial field, EDTA dipotassium can be used to remove the adverse effects of metal ions and prevent oxidation and deterioration caused by metal ions .
    EDTA dipotassium dihydrate
  • HY-10274A
    Dabigatran etexilate mesylate
    4 Publications Verification

    BIBR 1048MS; Dabigatran etexilate methanesulfonate

    		 Thrombin Cardiovascular Disease
    Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate mesylate
  • HY-15664
    Bivalirudin TFA
    Maximum Cited Publications
    9 Publications Verification

    		 Thrombin Interleukin Related RSV Infection Cardiovascular Disease Inflammation/Immunology
    Bivalirudin TFA, a hirudin analog and anticoagulant, is a direct thrombin inhibitor. Bivalirudin TFA inhibits thrombin-mediated fibrinogen cleavage, coagulation factor activation, and platelet activation by reversibly binding to thrombin. In addition, Bivalirudin TFA also has certain effects of anti-virus, anti-inflammation, and vascular endothelial barrier function protection. Bivalirudin TFA can be used for the research of thrombotic diseases and others .
    Bivalirudin TFA
  • HY-111186
    Flocoumafen

    WL 108366

    		 Glucocorticoid Receptor MMP VKOR Others
    Flocoumafen (WL 108366) is an orally active vitamin K epoxide reductase inhibitor and a multi-target ligand, which includes prostaglandin F synthase, serum albumin, glucocorticoid receptor 2, and MMP-9. Flocoumafen is a second-generation anticoagulant rodenticide (ARs) with a half-life of 177.4 hours and has deadly anticoagulant effects .
    Flocoumafen
  • HY-P99794
    Osocimab

    BAY 1213790

    		 Factor Xa Cardiovascular Disease
    Osocimab (BAY 1213790), an anti-FXIa antibody (Ki=2.4 nM; EC50=0.2 nM). FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects .
    Osocimab
  • HY-N1400
    (20R)-Ginsenoside Rh1

    		PKC Cardiovascular Disease
    (20R)-Ginsenoside Rh1 is the R-isomer of Ginsenoside Rh1 (HY-N0604), and it is found in red ginseng, ginseng, and other sources. (20R)-Ginsenoside Rh1 inhibits thrombin-induced conversion of fibrinogen to fibrin, exerting anticoagulant and antithrombotic effects .
    (20R)-Ginsenoside Rh1
  • HY-18660
    Ciraparantag

    PER977

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag
  • HY-P2933
    Activated protein C

    		Factor Xa Protease Activated Receptor (PAR) Cardiovascular Disease
    Activated protein C is an anticoagulant targeting coagulation factors Va and VIIIa. Activated protein C demonstrates cytoprotective effects through binding to endothelial cell protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1), regulating gene expression, anti-inflammation, anti-apoptosis, and stabilizing endothelial barriers. Activated protein C is promising for research of diseases such as severe sepsis and ischemic stroke .
    Activated protein C
  • HY-P4325
    Hirudin (55-65) sulfated

    		Thrombin Others
    Hirudin (55-65) (sulfated) is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property.
    Hirudin (55-65) sulfated
  • HY-108739
    Idarucizumab

    BI 655075

    		 Thrombin Cardiovascular Disease
    Idarucizumab is a humanized monoclonal antibody fragment. Idarucizumab is first reversal agent for a direct oral anticoagulant (DOAC). Idarucizumab can specifically neutralize the effects of the oral direct thrombin inhibitor in order to restore hemostasis .
    Idarucizumab
  • HY-10274R
    Dabigatran etexilate (Standard)

    BIBR 1048 (Standard)

    		 Reference Standards Thrombin Cardiovascular Disease
    Dabigatran etexilate (Standard) is the analytical standard of Dabigatran etexilate. This product is intended for research and analytical applications. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate (Standard)
  • HY-10274S
    Dabigatran etexilate-d13

    		Isotope-Labeled Compounds Thrombin Cardiovascular Disease
    Dabigatran etexilate-d13 is the deuterium labeled Dabigatran etexilate. Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran. Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate-d13
  • HY-14853
    Darexaban

    YM150

    		 Factor Xa Ser/Thr Protease Cardiovascular Disease
    Darexaban (YM150) is a potent, selective and orally active factor Xa (FXa) inhibitor with an IC50 of 54.6 nM. Darexaban shows high selectivity against other related serine proteases, such as trypsin, thrombin, and kallikrein. Darexaban has anticoagulant and antithrombotic effects .
    Darexaban
  • HY-15759A
    Napsagatran hydrate

    Ro 46-6240 hydrate; Ro 46-6240/010 hydrate

    		 Thrombin Cardiovascular Disease
    Napsagatran (Ro 46-6240) hydrate is a potent thrombin inhibitor. Napsagatran hydrate exhibits anticoagulant effects in vitro and in vivo. Napsagatran hydrate can be used in antithrombotic research [1][2].
    Napsagatran hydrate
  • HY-172316
    BAY 3389934

    		Factor Xa Cardiovascular Disease
    BAY 3389934 is a selective dual inhibitor of factor IIa and factor Xa, with an IC50 of 4.9 nM for factor IIa and an IC50 of 0.66 nM for factor Xa. BAY 3389934 directly inhibits the activities of factor IIa and factor Xa and regulates the common coagulation pathway. BAY 3389934 exhibits anticoagulant and organ-protective effects. BAY 3389934 can be used in the research of sepsis and coagulopathy .
    BAY 3389934
  • HY-172231
    Hexolame

    		Estrogen Receptor/ERR Cardiovascular Disease Cancer
    Hexolame is an estrogen receptors agonist with dual anticoagulant and estrogenic properties. Hexolame binds to estrogen receptors to induce anticoagulant effects by modulating clotting factors or platelet activity. Hexolame is promising for research of prostatic cancer and prevention of thrombosis .
    Hexolame
  • HY-10274AR
    Dabigatran etexilate mesylate (Standard)

    BIBR 1048MS (Standard); Dabigatran etexilate methanesulfonate (Standard)

    		 Reference Standards Thrombin Cardiovascular Disease
    Dabigatran etexilate (mesylate) (Standard) is the analytical standard of Dabigatran etexilate (mesylate). This product is intended for research and analytical applications. Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate mesylate (Standard)
  • HY-P1636A
    Hirudin (54-65) TFA

    		Thrombin Cardiovascular Disease
    Hirudin (54-65) TFA is a fragment of Hirudin with anticoagulant effects. Hirudin is a thrombin inhibitor with blood anticoagulant property .
    Hirudin (54-65) TFA
  • HY-18660A
    Ciraparantag TFA

    PER977 TFA

    		 Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag (PER977) TFA is a thrombin and factor Xa inhibitor. Ciraparantag TFA is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag TFA
  • HY-15759
    Napsagatran

    Ro 46-6240; Ro 46-6240/010

    		 Thrombin Cardiovascular Disease
    Napsagatran (Ro 46-6240) is a potent thrombin inhibitor. Napsagatran exhibits anticoagulant effects in vitro and in vivo. Napsagatran can be used in antithrombotic research [1][2].
    Napsagatran
  • HY-111186R
    Flocoumafen (Standard)

    WL 108366 (Standard)

    		 Reference Standards VKOR Glucocorticoid Receptor MMP Others
    Flocoumafen (Standard) is the analytical standard of Flocoumafen. This product is intended for research and analytical applications. Flocoumafen (WL 108366) is an orally active vitamin K epoxide reductase inhibitor and a multi-target ligand, which includes prostaglandin F synthase, serum albumin, glucocorticoid receptor 2, and MMP-9. Flocoumafen is a second-generation anticoagulant rodenticide (ARs) with a half-life of 177.4 hours and has deadly anticoagulant effects .
    Flocoumafen (Standard)
  • HY-18660S
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)

    PER977-d8 tetrahydrochloride diacetate

    		 Isotope-Labeled Compounds Factor Xa Thrombin Cardiovascular Disease
    Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660). Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban .
    Ciraparantag-d8 (tetra(hydrochloride) diacetate)
  • HY-W705434
    Dabigatran etexilate-d11

    BIBR 1048-d11

    		 Isotope-Labeled Compounds Thrombin Cardiovascular Disease
    Dabigatran etexilate-d11 (BIBR 1048-d11) is the deuterium labeled Dabigatran etexilate (HY-10274). Dabigatran etexilate (BIBR 1048) is an orally active proagent of Dabigatran (a direct inhibitor of thrombin). Dabigatran etexilate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation .
    Dabigatran etexilate-d11
  • HY-10275
    Atecegatran

    AR-H067637

    		 Thrombin Cardiovascular Disease
    Atecegatran (AR-H067637) is an orally active competitive thrombin inhibitor with a Ki of 2-4 nM. AR-H067637 inhibits platelet activation and aggregation by blocking thrombin binding to fibrin and thrombomodulin. Atecegatran demonstrates significant anticoagulant effects in various plasma coagulation assays, with an IC50 ranging from 93 to 220 nM. Atecegatran can be used in research related to thromboembolic disorders .
    Atecegatran
  • HY-N1400R
    (20R)-Ginsenoside Rh1 (Standard)

    		Reference Standards PKC Cardiovascular Disease
    (20R)-Ginsenoside Rh1 (Standard) is the analytical standard of (20R)-Ginsenoside Rh1 (HY-N1400). This product is intended for research and analytical applications. (20R)-Ginsenoside Rh1 is the R-isomer of Ginsenoside Rh1 (HY-N0604), and it is found in red ginseng, ginseng, and other sources. (20R)-Ginsenoside Rh1 inhibits thrombin-induced conversion of fibrinogen to fibrin, exerting anticoagulant and antithrombotic effects .
    (20R)-Ginsenoside Rh1 (Standard)
  • HY-14854A
    Tecarfarin sodium

    ATI-5923 sodium

    		 VKOR Cardiovascular Disease
    Tecarfarin (ATI-5923) sodium is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin sodium blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin sodium prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin sodium is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
    Tecarfarin sodium
  • HY-14854R
    Tecarfarin (Standard)

    ATI-5923 (Standard)

    		 Reference Standards VKOR Cardiovascular Disease
    Tecarfarin (ATI-5923) (Standard) is the analytical standard of Tecarfarin. This product is intended for research and analytical applications. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
    Tecarfarin (Standard)
  • HY-14854S
    Tecarfarin-13C,d3

    ATI-5923-13C,d3

    		 Isotope-Labeled Compounds VKOR Cardiovascular Disease
    Tecarfarin- 13C,d3 (ATI-5923- 13C,d3) is 13C labeled Tecarfarin. Tecarfarin is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .
    Tecarfarin-13C,d3
  • HY-183649
    BCN-PEG6-OH

    		Biochemical Assay Reagents Cardiovascular Disease
    BCN-PEG6-OH is a neutralizing agent and anticoagulant inhibitor containing strained alkyne. BCN-PEG6-OH undergoes strain-promoted alkyne-azide cycloaddition (SPAAC) click reaction with azido-Warfarin to generate an inactive product that can be rapidly cleared via the kidneys. In mice, BCN-PEG6-OH effectively reduces the anticoagulant activity of azido-Warfarin in a dose-dependent manner, normalizes prothrombin time, and exhibits no inherent anticoagulant or procoagulant effects when administered alone. BCN-PEG6-OH can be used for the research of drug-induced coagulopathy .
    BCN-PEG6-OH
  • HY-N18642
    Soapnut extract

    		Bacterial Infection Inflammation/Immunology
    Soapnut extract is a natural nonionic surfactant that can be used as a skin conditioning agent. It possesses strong detergency, antibacterial, non-polluting, and skin-softening properties. Soapnut extract also exhibits anti-inflammatory, antioxidant, free radical scavenging, and anticoagulant effects.
    Soapnut extract
  • HY-19517
    R1663

    		Endogenous Metabolite Cardiovascular Disease
    R1663 is a factor Xa inhibitor with anticoagulant activity. R1663 does not affect bleeding time. The pharmacodynamic effects (such as inhibition of thrombin generation) and plasma concentrations of R1663 are dose-dependent. R1663 prolongs clotting time in a concentration-dependent manner and inhibits the peak height of thrombin generation and endogenous thrombin potential .
    R1663
  • HY-W982689
    Fluindarol

    		Biochemical Assay Reagents Metabolic Disease
    Fluindarol is a phenylindandione derivative and an orally active anticoagulant. Fluindarol acts as a toxicant that induces organ and tissue haemorrhages and liver parenchymal necrosis in rats. Fluindarol exhibits acute and cumulative preclinical toxicity in rats, rabbits, and dogs, with higher toxicity in female rats than male rats. Fluindarol lacks analgesic action, produces only minor blood pressure effects, and does not alter circulation, respiration, CNS, or cardiac activity. Fluindarol is considered too toxic for clinical use based on preclinical data .
    Fluindarol
  • HY-106830
    Pelrinone

    		Phosphodiesterase (PDE) Cardiovascular Disease
    Pelrinone is an orally active cardiotonic agent and PDE III inhibitor with an IC50 of 36 μM. Pelrinone elevates intracellular cAMP levels. The action of Pelrinone is independent of β-adrenergic receptors, and it does not inhibit Na +/K +-ATPase. Pelrinone exerts positive inotropic and vasodilatory effects. Pelrinone inhibits platelet aggregation, reduces thrombus formation, and exerts weak anticoagulant activity without altering hematocrit or circulating platelet counts. Pelrinone can be used in research related to congestive heart failure and coronary thrombosis .
    Pelrinone

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: